Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Journal of Pain Research|December 14, 2022
Racial Differences in 25-Hydroxy Vitamin D and Self-Reported Pain Severity in a Sample of Individuals Living with Non-Specific Chronic Low Back PainDemario S Overstreet, Larissa J Strath, Fariha N Hasan, et al.
Journal of Clinical Medicine|February 11, 2021
Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-AnalysisWojciech Krajewski, Łukasz Nowak, Marco Moschini, et al.
Physical Chemistry Chemical Physics : PCCP|December 11, 2020
Hydroxide promotes ion pairing in the NaNO2-NaOH-H2O systemTrent R Graham, Mateusz Dembowski, Hsiu-Wen Wang, et al.
Talanta|October 5, 2025
147Nd quantification using HSCCC-purified samplesAlexander B Weberg, Mateusz Dembowski, Nathan C Smythe, et al.
Polish Archives of Internal Medicine|March 16, 2022
Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study)Maciej T Wybraniec, Aleksander Maciąg, Dawid Miśkowiec, et al.
Inorganic Chemistry|July 24, 2018
In Situ 27Al NMR Spectroscopy of Aluminate in Sodium Hydroxide Solutions above and below Saturation with Respect to GibbsiteTrent R Graham, Mateusz Dembowski, Ernesto Martinez-Baez, et al.
International Journal of Environmental Research and Public Health|April 23, 2022
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II StudyBeata Ceynowa-Sielawko, Maciej T Wybraniec, Aleksandra Topp-Zielińska, et al.
Kardiologia Polska|November 24, 2023
Antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation and sex differences: Insights from the CANT II StudyMaciej T Wybraniec, Aleksander Maciąg, Dawid Miśkowiec, et al.
Molecular Medicine (Cambridge, Mass.)|November 19, 2002
Erythropoietin therapy for acute stroke is both safe and beneficialHannelore Ehrenreich, Martin Hasselblatt, Christoph Dembowski, et al.
The Lancet. Oncology|July 17, 2015
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 studyPhilippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, et al.
Pageof 18